Research Nester published a report titled “Liver Cancer Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2031” which delivers detailed overview of liver cancer therapeutics in terms of market segmentation by type, therapy, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
The global of liver cancer therapeutics market is estimated to garner significant revenue by growing at a CAGR of 20.2% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to growing prevalence of liver cancer, and rise in incidence of hepatitis B infection in developing countries. According to the World Health Organisation, liver cancer was ranked third in the most common causes of cancer death in the world in 2020, causing nearly 830,000 deaths, while in 2019, hepatitis B resulted in an estimated 820,000 deaths globally. The market is segmented by type into hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others, out of which, the hepatocellular carcinoma segment is anticipated to hold the largest share in the global liver cancer therapeutics market over the forecast period. In 2018, there were an estimated number of 661,000 cases of hepatocellular carcinoma recorded worldwide, that contributed 80% of the world total liver cancer burden.
Geographically, the global liver cancer therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, North America is anticipated to hold the largest market share owing to high awareness about liver cancer, presence of well-established healthcare infrastructure, and easy drug availability. Additionally, Asia-Pacific region is estimated to witness growth at the highest rate during the forecast period.
Download Sample of This Strategic Report @ https://www.researchnester.com/sample-request-4114
The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.
Growing Prevalence of Liver Cancer and Advancement in Cancer Therapeutics with Emergence of Targeted Therapies to Boost Market Growth
Liver cancer is the sixth most common type of cancer in the world and recorded a number of 905,677 cases in 2020, as per statistics by the International Agency for Research on Cancer (IARC). Growing prevalence of liver cancer over high alcohol consumption, non-alcoholic fatty liver disease, is one of the key factors driving the growth of the market. Moreover, targeted therapy is considered a breakthrough in the field of medical oncology, which determined an improvement in the effectiveness of cancer treatments. Increasing R&D activities and advancement in targeted cancer therapies are also expected to foster the growth of the global liver cancer therapeutics market.
Curious about this latest version of report? Obtain Report Details @ https://www.researchnester.com/reports/liver-cancer-therapeutics-market/4114
However, high cost and side effects related to certain liver cancer therapies, and limitations in treatment options with several therapies in clinical trial stage are expected to restrain the growth of global liver cancer therapeutics market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global liver cancer therapeutics market which includes company profiling of Bristol-Myers Squibb Company, Eisai Co., Ltd., Exelixis, Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Bayer AG, Zymeworks Inc., F. Hoffmann-La Roche Ltd., Celsion Corporation, Eli Lilly and Company, AstraZeneca, among others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global liver cancer therapeutics market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Ask Industry Experts about this Report @ https://www.researchnester.com/sample-request-4114
About Research Nester
Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment, etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision so as to avoid future uncertainties.
U.S. Phone: [+1 646 586 9123]
U.K. Phone: [+44 203 608 591]